Theranos responds to the FDA's criticisms of its technology
Courtesy of Theranos
Among the concerns the FDA cited were problems with how Theranos documents its tests and its failure to get some of its proprietary technology approved.Now, Theranos has responded, giving some more context to the forms, which were issued after an August 25 visit from the FDA. The forms, called 483s, are issued at the end of inspections when investigators see anything that's not up to FDA standards.
Here are the main problems the FDA identified and Theranos' response to each of them.1. The way Theranos currently documents its tests isn't as clear as it should be.
Theranos' response: Theranos is currently in the process of moving from one set of lab rules (those that follow the Clinical Laboratory Improvement Amendments CLIA) to another (the FDA's), and the lack of clarity is a result of that transitioning process.2. Theranos' "nanotainers," the proprietary containers the company uses to collect blood, never got regulatory approval, so essentially they're being used illegally.Theranos' response: Part of their transition to the FDA's rules means that they've stopped using the nanotainers until they're explicitly cleared by the FDA.
Theranos says they've submitted documents to the FDA showing their progress in transitioning from CLIA's set of lab regulations to the FDA's.
- MPs should put pressure on Centre to include Kerala's demands in central budget:CM
- Final stage of Budget 2021-22 commences with Halwa ceremony
- Farmers' Protest: Local eateries facing tough time due to free langars at Singhu Border
- Venture Capital funding in India hits $3.1 billion in Q4 of 2020, says KPMG report
- A scary proposal to use facial recognition and AI by an Indian state has experts fuming